Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
Tag Archive for: CGT
Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure.
Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
British and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain.
Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
British researchers have proven that a new gene can prevent progression of hereditary kidney damage in mice.
BioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.
Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.
The world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh.
Bayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc.